MENLO PARK, Calif, July 7 /PRNewswire-FirstCall/ -- Corcept Therapeutics Incorporated today announced that the company will present at the C.E. Unterberg, Towbin Emerging Growth Conference on Tuesday, July 11 at 8:00 a.m. (EDT) at the Mandarin Oriental Hotel in New York. The presentation will cover the company's clinical and corporate progress.
A live and subsequent archive of the Corcept presentation will be available on July 11, 2006 via webcast at: http://www.wsw.com/webcast/ceut4/cort/
The webcast will be available for 2 weeks.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing drugs for treating severe psychiatric and neurological diseases. Corcept's lead product, CORLUX, is in Phase 3 clinical trials for treating the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to reduce the effects of the elevated and abnormal release patterns of cortisol seen in PMD. The company has also initiated a proof-of-concept study to evaluate the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. For more information, please visit www.corcept.com.
Corcept Therapeutics IncorporatedCONTACT: Fred Kurland, Chief Financial Officer of Corcept Therapeutics,+1-650-327-3270, or IR@corcept.com
Web site: http://www.corcept.com//
